Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.
Totaro R, Lugaresi A, Bellantonio P, Danni M, Costantino G, Gasperini C, Florio C, Pucci E, Maddestra M, Spitaleri D, Lus G, Ardito B, Farina D, Rossi M, Di Carmine C, Altobelli E, Maccarone B, Casalena A, De Luca G, Travaglini D, Di Ioia M, Di Tommaso V, Fantozzi R, Ruggieri S, Provinciali L, De Riso S, Mundi C, Fuiani A, Galgani S, Ruggieri S, Maniscalco GT, Giuliani G, Cartechini E, Petretta V, Fratta M, Alfieri G, Gatto M, Carolei A; Natalizumab Long-Term Treatment Study group. Totaro R, et al. Among authors: maniscalco gt. Int J Immunopathol Pharmacol. 2014 Apr-Jun;27(2):147-54. doi: 10.1177/039463201402700201. Int J Immunopathol Pharmacol. 2014. PMID: 25004826 Free article.
Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
Maniscalco GT, Liotti A, Ferrara AL, Prestipino E, Salvatore S, Di Battista ME, Moreggia O, Di Giulio Cesare D, Vastano R, Belardo M, Napolitano M, Ranieri A, Longo K, Andreone V, De Rosa V. Maniscalco GT, et al. Mult Scler Relat Disord. 2022 Dec;68:104371. doi: 10.1016/j.msard.2022.104371. Epub 2022 Oct 23. Mult Scler Relat Disord. 2022. PMID: 36544318 Free PMC article.
SARS-CoV-2 antibodies in inflammatory neurological conditions: a multicentre retrospective comparative study.
Zivelonghi C, Dinoto A, Irani SR, McKeon A, Pilotto A, Padovani A, Masciocchi S, Magni E, Mancinelli CR, Capra R, Maniscalco GT, Volonghi I, Easton A, Alberti D, Zanusso G, Monaco S, Salvagno GL, Lippi G, Ferrari S, Mariotto S. Zivelonghi C, et al. Among authors: maniscalco gt. Immunol Res. 2023 Oct;71(5):717-724. doi: 10.1007/s12026-023-09384-2. Epub 2023 May 12. Immunol Res. 2023. PMID: 37171542 Free PMC article.
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A; BRIDGE study group. Lugaresi A, et al. BMC Neurol. 2012 Mar 5;12:7. doi: 10.1186/1471-2377-12-7. BMC Neurol. 2012. PMID: 22390218 Free PMC article. Clinical Trial.
The Framingham cardiovascular risk score in multiple sclerosis.
Moccia M, Lanzillo R, Palladino R, Maniscalco GT, De Rosa A, Russo C, Massarelli M, Carotenuto A, Postiglione E, Caporale O, Triassi M, Brescia Morra V. Moccia M, et al. Among authors: maniscalco gt. Eur J Neurol. 2015 Aug;22(8):1176-83. doi: 10.1111/ene.12720. Epub 2015 Apr 27. Eur J Neurol. 2015. PMID: 25912468
123 results